Kylin Therapeutics receives funding for cancer treatment research
November 12, 2010
November 10, 2010
WEST LAFAYETTE, Ind. – Officials of Kylin Therapeutics Inc. announced Wednesday (Nov. 10) that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.
The nearly $250,000 award from the IRS is in the form of a grant designed for biotechnology research and development that is critical for the advancement of new therapies. The grants are administered through the U.S. Department of Health and Human Services.
Kylin's pRNAi is a nanotechnology platform that leverages the power of RNA and a natural process called RNA interference (RNAi) to directly target and "turn off" disease-causing genes.
"This grant is important because it will enable us to invest more in the research we are doing in the field of RNA interference," said Eric Davis, president and CEO of Kylin Therapeutics. "The pRNA research we are doing could provide a self-delivering cancer treatment that could give physicians a new drug delivery method in the treatment of cancer and other diseases."
Criteria for the therapeutic discovery project grant include the potential to:
* Result in new therapies to treat areas of unmet medical need or to prevent, detect or treat chronic or acute diseases.
* Reduce the long-term growth of health-care costs in the United States.
* Significantly advance the goal of curing cancer by 2040.
* Create and sustain high-quality, high-paying U.S. jobs.
* Advance U.S. competitiveness in life, biological and medical sciences.
Kylin's patented technology was discovered by Peixuan Guo, who developed the pRNA technology when he was a professor of molecular virology and biomedical engineering and faculty scholar at Purdue University. Guo served as director of Purdue's Nanobiotechnology Interdisciplinary Graduate Program and as director of a NIH Nanomedicine Development Center. He is now an endowed professor and director of the Nanomedicine Bionanotechnology Center at the University of Cincinnati.
About Kylin Therapeutics Inc.
Kylin Therapeutics, Inc., a biotechnology company based in the Purdue Research Park, employs a RNA nanoparticle technology platform called "pRNA" to exploit the potential of oligonucleotides for treatment of many common diseases. Its goal is to use RNA building blocks to build ideal therapeutic nanotechnologies to address unmet medical needs. This platform has enormous potential to combine into one nanoparticle all possible RNA functionalities including receptor antagonism/activation, cell targeting/delivery and gene knockdown through mechanisms like RNA interference.
January 30, 2015
Enterovirus D68 (EV-D68) is a member of Picornaviridae and is a causative agent of recent outbreaks of respiratory illness in children in the United States. We report here the crystal structures of EV-D68 and its complex with pleconaril, a capsid-binding compound that had been developed as an anti-rhinovirus drug. The hydrophobic drug-binding pocket in viral protein 1 contained density that is consistent with a fatty acid of about 10 carbon atoms. This density could be displaced by pleconaril. We also showed that pleconaril inhibits EV-D68 at a half-maximal effective concentration of 430 nanomolar and might, therefore, be a possible drug candidate to alleviate EV-D68 outbreaks.Read Full Story
January 12, 2015
Five Purdue University researchers received nearly $150,000 from the Trask Innovation Fund to further develop their technologies. The innovations originate from multiple disciplines and range from water purification to a drug-delivery technology.Read Full Story
December 18, 2014
Three Purdue University professors have been named fellows of the National Academy of Inventors.Read Full Story